Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
After the transaction, it will be NovaBay’s largest shareholder with 6.6 million shares, 37% of the total.
Nanjing Legend Biotech received a very large $350M upfront payment from Janssen Biotech to partner Legend’s impressively effective CAR-T candidate.
Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds.
Arno Therapeutics is calling it quits. It sold off all its assets, with the final asset being the rights to Onapristone, which it sold to Context Biopharma.
Roche got in some last-minute Christmas shopping, shelling out $1.7B for San Diego’s Ignyta.
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
Takeover whispers boosted long-standing target Shire to the top of the FTSE 100 as the pharma firm’s shares rallied on hopes of a mega deal bringing shareholders an early Christmas present.
Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.
Ultragenyx CEO Emil Kakkis said the sale of the PRV will provide the company with an “important source of non-dilutive capital” that will be used to advance the company’s pipeline of rare and ultra-rare therapies.